Table 3.
Clones with frequent DNA amplification in breast cancer cell lines and primary tumor tissues
| Chromosomal region | Candidate genes | No, of tumors | Frequency (%) |
|---|---|---|---|
| Cell lines (n = 24) | |||
| 17q12 | NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, PERLD1 | 10 | 41.7 |
| 17q12 | PERLD1, ERBB2, GRB7, ZNFN1A3 | 10 | 41.7 |
| 17q21.1 | ZNFN1A3, ZPBP2, GSDML, ORMDL3, GSDM1, PSMD3 | 8 | 33.3 |
| 8q24.13 | ZHX2 | 7 | 29.2 |
| 5p15.33 | TPPP, LOC442127, ZDHHC11 | 6 | 25.0 |
| 8q24.12 | SAMD12 | 6 | 25.0 |
| 8q24.12 | MRPL13, MTBP, SNTB1 | 6 | 20.5 |
| 8q24.22 | TG, | 6 | 25.0 |
| 20q13.2 | BCAS1, CYP24A1 | 6 | 25.0 |
| 20q13.2 | BCAS1 | 6 | 25.0 |
| 20q13.2 | DOK5 | 6 | 25.0 |
| 20q13.2 | DOK5 | 6 | 25.0 |
| 20q13.32 | PCK1, ZBP1, TMEPAI, | 6 | 25.0 |
| Tumor tissues (n = 35) | |||
| 17q12 | NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, PERLD1 | 7 | 20.0 |
| 17q12 | PERLD1, ERBB2, GRB7, ZNFN1A3 | 8 | 17.1 |
| 17q21.1 | ZNFN1A3, ZPBP2, GSDML, ORMDL3, GSDM1, PSMD3 | 6 | 17.7 |
| 8p12 | - | 5 | 14.3 |
| 8q21.11 | PI15 | 5 | 14.3 |
| 8q21.11 | ZFHX4 | 5 | 14.3 |
| 8q24.21 | DDEF1 | 5 | 14.3 |
| 17q23.3 | TEX2 | 5 | 14.3 |
| 8p12 | WHSC1L1, LETM2, FGFR1 | 4 | 11.4 |
| 8p12-8p11.23 | LETM2, FGFR1 | 4 | 11.4 |
| 8p11.23 | TACC1, PLEKHA2 | 4 | 11.4 |
| 8q21.11 | - | 4 | 11.4 |
| 8q21.12 | IL7 | 4 | 11.4 |
| 8q21.3 | RUNX1T1 | 4 | 11.4 |
| 8q22.1 | - | 4 | 11.4 |
| 8q22.3 | - | 4 | 11.4 |
| 8q23.3 | - | 4 | 11.4 |
| 8q24.11 | - | 4 | 11.4 |
| 8q24.13 | - | 4 | 11.4 |
| 17q23.3 | CSH1, CSHL1, GH1, CD79B, SCN4A | 4 | 11.4 |
-: The relevant clone harbors no genes identified.
The number of clones with DNA amplification that is detected in more than 10% of samples is 101 clones in the cell lines, while it is only 20 clones in tumor tissues.